stoxline Quote Chart Rank Option Currency Glossary
  
Cellectis S.A. (CLLS)
1.55  0.02 (1.33%)    02-14 16:00
Open: 1.6099
High: 1.6099
Volume: 77,524
  
Pre. Close: 1.5297
Low: 1.515
Market Cap: 116(M)
Technical analysis
2025-02-14 4:47:04 PM
Short term     
Mid term     
Targets 6-month :  2.04 1-year :  2.25
Resists First :  1.74 Second :  1.92
Pivot price 1.55
Supports First :  1.45 Second :  1.2
MAs MA(5) :  1.52 MA(20) :  1.55
MA(100) :  1.81 MA(250) :  2.19
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  26.2 D(3) :  23.3
RSI RSI(14): 46.3
52-week High :  3.38 Low :  1.4
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ CLLS ] has closed above bottom band by 47.2%. Bollinger Bands are 62.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 8 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 1.61 - 1.62 1.62 - 1.62
Low: 1.5 - 1.51 1.51 - 1.51
Close: 1.54 - 1.55 1.55 - 1.56
Company Description

Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART22 to treat B-cell acute lymphoblastic leukemia. It is also developing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. The company has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; and Iovance Biotherapeutics, as well as a strategic research and development collaboration with Cytovia Therapeutics, Inc. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.

Headline News

Wed, 05 Feb 2025
Cellectis S.A. (NASDAQ:CLLS) Short Interest Update - MarketBeat

Sat, 18 Jan 2025
Short Interest in Cellectis S.A. (NASDAQ:CLLS) Expands By 59.7% - MarketBeat

Tue, 07 Jan 2025
Do Options Traders Know Something About Cellectis (CLLS) Stock We Don't? - Nasdaq

Sun, 29 Dec 2024
Analysts Predict 400% Upside Potential for This Penny Stock - GuruFocus.com

Thu, 12 Dec 2024
Cellectis: Poised To Start Answering Questions In 2025 (NASDAQ:CLLS) - Seeking Alpha

Tue, 10 Dec 2024
Cellectis announces the drawdown of the third tranche of €5 million under the credit facility agreement entered with the European Investment Bank (EIB) - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Neutral
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 100 (M)
Shares Float 71 (M)
Held by Insiders 3.8 (%)
Held by Institutions 15.3 (%)
Shares Short 165 (K)
Shares Short P.Month 127 (K)
Stock Financials
EPS -1.16
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 1.28
Profit Margin -234.4 %
Operating Margin -59.7 %
Return on Assets (ttm) -16.1 %
Return on Equity (ttm) -82.2 %
Qtrly Rev. Growth 998 %
Gross Profit (p.s.) 0.35
Sales Per Share 0.36
EBITDA (p.s.) -0.68
Qtrly Earnings Growth 0 %
Operating Cash Flow 63 (M)
Levered Free Cash Flow -14 (M)
Stock Valuations
PE Ratio -1.34
PEG Ratio 0
Price to Book value 1.2
Price to Sales 4.3
Price to Cash Flow 2.47
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android